PARP1 and cancer: Regorafenib’s anti-cancer effect, i.e., induction of apoptosis was further demonstrated at the protein level, by activation of PARP-1 cleavage protein expression in a dose-dependent manner when compared with control co-culture cells (Figure 5B).